Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155190 · ClinicalTrials.gov registry record · Phase 2
An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
A Phase 2 study, sponsored by Sol-Gel Technologies.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT04155190 is a Phase 2 study that was terminated before completion, run by Sol-Gel Technologies. The registered enrollment target is 47 participants.
The verdict
NCT04155190, a Phase 2 study, was terminated before completion, sponsored by Sol-Gel Technologies.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with non-Gorlin HF-BCC (high-frequency basal cell carcinoma). Participants will be randomized (1:1) to receive either Patidegib Topical Gel, 2%, or Vehicle for 9 months. Randomization will be stratified by gender. The primary endpoint is the number of nSEB (surgically eligible basal cell carcinoma) that develop on the face over the 9 month period. The primary end point will be assessed by imaging and tracking of BCCs consistently throughout the study in order to identify nSEBs.
Interventions
- DRUG Patidegib Topical Gel, 2%
- DRUG Patidegib Topical Gel, Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2019-12-20 |
| Est. Completion | 2021-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04155190
The ClinicalTrials.gov registry entry for NCT04155190 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sol-Gel Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Patidegib Topical Gel, 2% is the first listed.
NCT04155190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04155190 about?
NCT04155190 is a clinical study titled "An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC". This is a multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with non-Gorlin HF-BCC (high-frequency basal cell carcinoma). Participants will be randomized...
What is the current status of trial NCT04155190?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2019-12-20. Estimated completion is 2021-04-23.
What interventions are being tested in trial NCT04155190?
The interventions under investigation include: Patidegib Topical Gel, 2% (DRUG), Patidegib Topical Gel, Vehicle (DRUG).
Who is sponsoring clinical trial NCT04155190?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.